Logo

Monitoring uptake and effectiveness of COVID-19 vaccine in the WHO European Region - Shared screen with speaker view
Radu Botgros
38:58
there is noise on the line
Radu Botgros
39:17
probably from the headphones
Adam Finn
39:27
No noise for me
WHO MNE_MINA BRAJOVIC
44:14
the voice resonates ..it seems it s due to the equipment
Radu Botgros
56:24
not all these data are updated, what is the frequency of the updates?
Gazmend Bejtja
57:03
Not updated
Roberta Pastore
59:31
Frequency of update is weekly. Dashboards are based on data reported as of Tuesdays, reporting data up to previous week. Updates are published on Wednesdays
Geert Top
59:47
is this public? link?
Radu Botgros
01:00:29
https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/
Roberta Pastore
01:00:58
It is public. https://worldhealthorg.shinyapps.io/EURO_COVID-19_vaccine_monitor/
Veronika Učakar; NIJZ, slovenia
01:01:40
Slovenia is reporting data regularly to Tessy every Tuesday. So why are we in white color in all the maps?
Radu Botgros
01:09:25
@Nathalie: biweekly may mean twice per week or every two weeks-i understand that here it is twice per week
WHO MNE_MINA BRAJOVIC
01:10:16
please can you share the link for the ecdc tracker as well
Jose Hagan (WHO/EURO)
01:10:32
Thank you for pointing this out, Veronica! Your data are included in the tables but I see that there is obviously an issue with the map shape file that I did not notice before. Sincere apologies for this oversight - we will correct this right away.
Veronika Učakar; NIJZ, slovenia
01:11:00
Thank you very much.
Radu Botgros
01:12:14
https://qap.ecdc.europa.eu/public/extensions/COVID-19/vaccine-tracker.html#uptake-tab
Jose Hagan (WHO/EURO)
01:23:56
Veronika, the app has been updated - thank you again for pointing out the problem and apologies for the oversight.
Verica Jovanovic Serbia
01:29:15
Can we expect that these ppt will be available after this meeting? Thank you in advance, Verica, IPH Batut, Serbia
Roberta Pastore
01:30:46
Slides will be shared after the webinar
Richard Pebody
01:30:49
We will be sharing the slides with the permission of the speakers.
Verica Jovanovic Serbia
01:34:00
Thank you
Nathalie Nicolay (ECDC)
01:35:06
@Radu : Sorry for the confusion - Bi weekly means twice a week : Every Tuesday and every Friday
Roberta Pastore
01:55:40
For the outputs of WHO monthly monitoring, dashboards and reports will be available
Nick Andrews
02:08:13
In the paper I was looking at the negative control period in the hospital data. This seems to show a lower risk in the vaccinated across the whole control period (about 50% lower)? In other studies I see the same where with a hospital outcome and using date of hospitalisation as the event date there is a reasonably long healthy vaccinee effect, which is probably not surprising.
Kari Johansen
02:10:29
What is the definition on severe disease, thanks.
Jim McMenamin
02:25:54
For those interested in the pre-publication version of the Paper from Scotland please see - https://www.ed.ac.uk/files/atoms/files/scotland_firstvaccinedata_preprint.pdf
Kari Johansen
02:41:44
Dear Jamie, thanks for a beautiful presentation. Will you continue analyses every week or so moving forward so we will learn more of the long-term effectiveness?
Jamie Lopez Bernal
02:47:10
Yes, we continue to run these weekly and happy to report again in future (case numbers are coming down though so the additional follow-up is not contributing as much additional information)
Jamie Lopez Bernal
02:49:23
Preprints are available here:
Adam Finn
02:50:06
Hearing Jim fine throughout - maybe it’s you Richard
Adam Finn
02:51:08
Bristol Avon CAP preprint is at https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3796835
Jamie Lopez Bernal
02:51:22
Preprints are available here: Routine testing: https://www.medrxiv.org/content/10.1101/2021.03.01.21252652v1 . SIREN https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3790399. AvonCAP (Bristol) study: https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3796835
Natasha Crowcroft, WHO HQ
02:56:42
Such wonderful presentations today - all of them! Thanks to each and every one of the speakers. I have a specific question - is PHE is planning a stratified analysis of VE by ethnicity ?
Mark Katz
03:12:09
@Kari Johansen. The definition of severe disease in the Israel study that Ran presented is based on the NIH definition: Severe Illness: Individuals who have SpO2 <94% on room air at sea level, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen (PaO2/FiO2) <300 mm Hg, respiratory frequency >30 breaths/min, or lung infiltrates >50%.https://www.covid19treatmentguidelines.nih.gov/overview/clinical-spectrum/
Maja Stosic
03:17:15
Congratulations to colleagues from IPH Albania